New Study Identifies Four Blood Biomarkers Linked to PTSD Risk, Diagnosis and Treatment Response

Summary: A large prospective study shows four blood-based biomarkers — glycolytic ratio, arginine, serotonin and glutamate — display distinct patterns in service members with current or emerging post‑traumatic stress disorder (PTSD). These markers have potential for screening, diagnostic support and monitoring treatment response.

Source: ASBMB

Overview

A new study involving more than 1,000 active-duty service members found consistent changes in four measurable blood biomarkers among people with PTSD or at high risk for developing it. The research tracked participants before deployment, shortly after their return and several months later to identify biological signals associated with post‑traumatic stress over time.

PTSD is a psychiatric condition that can follow exposure to traumatic events and is diagnosed based on symptoms such as intrusive memories or flashbacks, sleep disturbances, trouble concentrating, persistent negative thoughts and avoidance of reminders of the trauma. Because many mental health disorders share similar symptoms, objective biological measures could improve detection, diagnosis and tracking of recovery or relapse.

This study is the largest prospective investigation to date to measure biological markers of PTSD longitudinally in a military cohort, offering new insight into the disorder’s biological footprint and how those signals change with exposure and recovery.

Stacy‑Ann Miller of the Walter Reed Army Institute of Research, a lead investigator on the project, said the findings enhance understanding of PTSD’s natural history and could inform more effective screening and treatment strategies by identifying individuals at higher risk and monitoring therapeutic responses.

Study design and biomarker selection

Researchers analyzed blood samples collected at three time points: prior to a roughly 10‑month deployment, three days after participants returned, and three to six months after return. The team focused on four biomarkers previously linked to stress, mood disorders and neural function:

• Glycolytic ratio — an indicator of how the body processes glucose for energy;
• Arginine — an amino acid involved in immune and cardiovascular systems;
• Serotonin — a neurotransmitter that helps regulate mood, sleep and other functions;
• Glutamate — a key excitatory neurotransmitter important for learning and memory.

Participants were grouped by clinical measures into those with diagnosed PTSD, those with sub‑threshold PTSD symptoms, and those without PTSD. Separately, the team classified psychological resilience using multiple factors including anxiety levels, sleep quality, alcohol use, combat exposure, traumatic brain injury history, and overall physical and mental health. Previous work has shown low resilience across these factors is associated with greater risk of developing PTSD after deployment.

Key findings

Compared with participants classified as highly resilient, those with PTSD or sub‑threshold PTSD showed a pattern of higher glycolytic ratio and lower arginine. They also exhibited lower circulating serotonin levels and higher glutamate levels. These associations remained significant after accounting for demographic and lifestyle factors such as age, sex, body mass index, smoking and caffeine intake.

The pattern suggests a coordinated set of metabolic and neurotransmitter changes linked to PTSD risk and presence. While the study does not establish causation, the reproducible associations across time points support the potential utility of these biomarkers in clinical contexts.

Implications for screening, diagnosis and treatment

The researchers propose that measuring these four biomarkers from simple blood samples could complement existing clinical assessments. Potential applications include identifying individuals at higher risk for developing PTSD after trauma exposure, improving diagnostic accuracy when symptoms overlap with other disorders, and objectively monitoring biological response to interventions over time.

Miller noted that more accurate screening and prediction methods could enable earlier, more targeted interventions and may help tailor treatments to specific biological profiles or PTSD subtypes, which in turn could improve outcomes.

Next steps and caution

The authors emphasize that further validation is required before these biomarkers can be implemented in routine practice. Additional studies are needed in diverse populations and clinical settings to confirm reliability, determine thresholds for clinical decision‑making, and evaluate how best to integrate biomarker data with psychological assessment.

Collaboration

This work was carried out in partnership with the PTSD Systems Biology Consortium and involved researchers from the Walter Reed Army Institute of Research, the Institute for Systems Biology, New York University Langone Medical Center, Icahn School of Medicine at Mount Sinai, University of California San Francisco, Harvard University and the University of Memphis, among others.

About this PTSD research news

Author: Anne Johnson
Source: ASBMB
Contact: Anne Johnson – ASBMB
Image: The image is in the public domain

Original Research: Findings will be presented at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology